J-Pharma Co.,Ltd. (520A.T)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in JPYTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | - | - | - | - | - | - | - | - |
| Operating profit | ¥m | - | |||||||
| Net profit | ¥m | - | - | - | - | - | - | - | - |
| EPS reported | ¥ | - | |||||||
| Operating cashflow per share | ¥ | - | |||||||
| Capex per share | ¥ | - | |||||||
| FCF per share | ¥ | - | |||||||
| Free cash flow | ¥m | - | |||||||
| Net debt | ¥m | - | |||||||
| Book value equity | ¥m | - | |||||||
| Book value per share | ¥ | - | |||||||
| Number of shares | m | - | |||||||
| DPS (TTM paid) | ¥ | - |
Financial summary
Financials in JPYTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | |||||||
| P/B LTM | x | - | |||||||
| P/S LTM | x | - | |||||||
| P/FCF LTM | x | - | |||||||
| EV/EBITDA LTM | x | - | |||||||
| EV/Sales LTM | x | - | |||||||
| Earnings Yield LTM | % | - | |||||||
| FCF Yield | % | - | |||||||
| Quality | |||||||||
| ROE | % | - | |||||||
| ROIC | % | - | |||||||
| Operating margin | % | - | |||||||
| Gross margin | % | - | |||||||
| FCF/Sales | % | - | |||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | |||||||
| Sales Growth YoY | % | - | |||||||
| Net Income Growth YoY | % | - | |||||||
| FCF Growth | % | - | |||||||
| Operating Profit Growth | % | - | |||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | - | |||||||
| Dividend Growth | % | - | |||||||
| Payout Ratio | % | - | |||||||
| FCF/Debt | x | - | |||||||
| Net Debt/EBITDA | x | - | |||||||
| EBIT/Net interest | x | - | |||||||
| Net debt/market cap | % | - | |||||||
| Net debt/Equity | x | - | |||||||
| Gross debt/equity | x | - | |||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company conducts functional and structural analysis of selected SLC transporters to support drug discovery, collaborates with academic institutions, and participates in joint research for new pharmaceutical development. It is preparing for clinical trials and global distribution of its drug candidates. The company was founded in 2005 and is based in Yokohama, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company conducts functional and structural analysis of selected SLC transporters to support drug discovery, collaborates with academic institutions, and participates in joint research for new pharmaceutical development. It is preparing for clinical trials and global distribution of its drug candidates. The company was founded in 2005 and is based in Yokohama, Japan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free